News coverage about Geron (NASDAQ:GERN) has been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Geron earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.9658726588266 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

Geron (NASDAQ:GERN) opened at $2.98 on Wednesday. The company has a market capitalization of $474.51, a PE ratio of -16.56 and a beta of 2.77. Geron has a twelve month low of $1.74 and a twelve month high of $3.24.

A number of equities research analysts have weighed in on GERN shares. BidaskClub upgraded Geron from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 11th. Zacks Investment Research downgraded Geron from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $3.33.

WARNING: “Geron (GERN) Receives News Impact Rating of 0.16” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at

Geron Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Insider Buying and Selling by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with's FREE daily email newsletter.